

THE ROLE OF LACTIC ACID IN THE MANAGEMENT OF BACTERIAL VAGINOSIS: A Systematic Literature Review

W. Mendling, M. Atef El Shazly and L. Zhang



Objectives

- > **Review of the efficacy and prophylactic potential of lactic acid** for BV alone or with antibiotics.
- > **Propose additional treatment recommendations** based on clinical findings.

Method

- > **Systematic literature review** on PubMed and Cochrane Library databases from inception until 7 May 2021.

Results

- > 213 peer-reviewed studies identified
- > 12 fulfilled inclusion criteria and assessed for eligibility
- > 7 articles eligible and included

Efficacy of Lactic Acid



On symptomatic BV

Mixed data

2 studies = similar cure rates as metronidazole.
1 study = greater efficacy over placebo.
2 studies = no increase cure rates over placebo.



On recurrent BV

Intermittent prophylactic use of vaginal lactate gel was **significantly higher than placebo**.



During pregnancy

After 2 days = Positive change in the vaginal microbiota.
After 1 week = with 80% cure rate.

Discussion

Variation in efficacy results might be partly due to generalization of the study population, **despite different grades of BV severity**, and the **administration route** and might indicate that an **alternative patient population stratification** is desired:

Patient Group	Condition	Lactic Acid	Antibiotics	Antifungal
First time BV	Mild BV	Vaginal lactic acid, 5 mL, 7 days	No	No
	Moderate/Severe BV	Vaginal lactic acid, 5 mL, 7 days	Oral metronidazole, 7 days, or Vaginal metronidazole or clindamycin, 5-7 days	No
Recurrent BV		Vaginal lactic acid, 5 mL, 7 days	Vaginal metronidazole, 4-6 months, or Oral metronidazole or tinidazole, 7 days	No
Pregnant with BV	Symptomatic	Vaginal lactic acid, 5 mL, 7 days	Oral metronidazole or clindamycin, 7 days, or Vaginal dequalinium, metronidazole, or clindamycin	No
	Asymptomatic and at high risk of preterm birth	Vaginal lactic acid, 5 mL, 7 days	No	No
Planning pregnancy	Asymptomatic mild BV	Vaginal lactic acid, 5 mL, 7 days	No	No
Mixed infection	BV and VVC	Vaginal lactic acid, 5 mL, 7 days, only if BV symptoms persist after VVC treatment	Only if BV symptoms persist after VVC treatment, and depending on the patient group	Vaginal clotrimazole, single dose
	BV and trichomoniasis	Vaginal lactic acid, 5 mL, 7 days	Oral metronidazole or tinidazole, single dose	No

BV: Bacterial Vaginosis; VVC Vulvovaginal Candidosis.

Conclusion

Although initial treatment with antibiotics is very effective, the prevention of BV recurrence remain an important challenge. **Concomitant usage of lactic acid-based treatments could provide added value by stimulating restoration of the healthy vaginal microbiota and disrupting pathogenic biofilms**, thereby aiding in the treatment of BV and prevention of recurrent infections.

Additional Information: This is a manuscript summary of the original research article published : Mendling,W.; Shazly, M.A.E.; Zhang, L. The Role of Lactic Acid in the Management of Bacterial Vaginosis: A Systematic Literature Review. Future Pharmacol. 2022, 2, 198–213. <https://doi.org/10.3390/futurepharmacol2030014>. This review was funded by Bayer Consumer Care AG, Basel, Switzerland. Writing assistance was provided by Leni Vandekerckhove (MediGraphX, Belgium) and Jonathan Crowther (JMC Scientific Consulting Ltd., United Kingdom).
CH-20250905-47